Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

STERIS plc, a public limited company organized under the laws of England and Wales, was incorporated on October 9, 2014 as a private limited company under the name New STERIS Limited and was re-registered effective November 2, 2015 as a public limited company under the name STERIS plc. New STERIS Limited was established to effect the combination (“Combination”) of STERIS Corporation, an Ohio corporation (“Old STERIS”), and Synergy Health plc, a public limited company organized under the laws of England and Wales (“Synergy”). The Combination closed on November 2, 2015 and as a result STERIS plc became the ultimate parent company of Old STERIS and Synergy. Synergy has been re-registered under the name Synergy Health Limited. The acquisition of Old STERIS was accounted for in the consolidated financial statements as a merger between entities under common control; accordingly the historical consolidated financial statements of Old STERIS for periods prior to November 2, 2015, are considered to be the historical financial statements of STERIS plc. Due to the timing of the Combination, the results of Synergy are only reflected in the results of operations of the Company from November 2, 2015, forward will affect the comparability to the prior period historical operations of the Company throughout this Quarterly Report on Form 10-Q.

STERIS develops, manufactures and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental Customers throughout the world.

As a result of the Combination, we have reorganized our operations into four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. We describe our business segments in note 10 to our consolidated financial statements titled, “Business Segment Information.”

Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:

Interim Financial Statements

We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.

These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015. The Consolidated Balance Sheet at March 31, 2015 was derived from the audited consolidated financial statements at March 31, 2015, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

Principles of Consolidation

We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. In prior periods we presented income attributable to noncontrolling interests in the "Interest income and miscellaneous expense" line of our Consolidated Statements of Income and the amounts were not material.

Use of Estimates

We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2015 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2016.

Recent Accounting Pronouncements

Recently issued accounting standards impacting the Company are presented in the following table:



Standard	Date of Issuance	Description	Date of Adoption	Effect on the financial statements or other significant matters
Standards that have recently been adopted
ASU 2015-16, "Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments"	September 2015	The standard requires the recognition of adjustments to provisional amounts, that are identified during the measurement period, in the reporting period in which the adjustments are determined. The effects of the adjustments to provisional amounts on depreciation, amortization or other income effects should be recognized in current-period earnings as if the accounting had been completed at the acquisition date. Disclosure of the portion of the adjustment recorded in current-period earnings that would have been reported in prior reporting periods if the adjustment to the provisional amounts had been recognized at the acquisition date is also required.	Third Quarter Fiscal 2016	This update did not have a material impact on our consolidated financial position, results of operations or cash flows.
ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs"	April 2015	The update requires capitalized debt issuance costs to be presented as a reduction to the carrying value of debt instead of being classified as a deferred charge, as previously required. This update is effective for all annual and interim periods beginning after December 15, 2015 and is required to be adopted retroactively for all periods presented. Early adoption was permitted.	First Quarter Fiscal 2016	This update did not have a material impact on our consolidated financial position, results of operations or cash flows.
Standards that have not yet been adopted
ASU 2014-09, "Revenue from Contracts with Customers"	May 2014	The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is not permitted before the original public entity effective date of December 15, 2016.	N/A	We are currently in the process of evaluating the impact that the standard will have on our consolidated financial position, results of operations and cash flows.



ASU 2015-05, "Goodwill and other - Internal-Use Software" (Subtopic 350-40)	April 2015	The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted.	N/A	We are currently in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.
ASU 2015-17, "Income Taxes Balance Sheet Classification of Deferred Taxes" (Topic 740)	November 2015	The update will require all entities that present a classified statement of financial position classify all deferred tax liabilities and assets as noncurrent in the statement. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount will not be affected by the Update.The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted.	N/A	We are currently in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.

A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in Old STERIS's consolidated financial statements included in its Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2015.

Reclassifications out of AOCI (Notes)

9 Months Ended

Dec. 31, 2015

Reclassifications out of AOCI [Abstract]

Comprehensive Income (Loss) Note [Text Block]

Reclassifications Out of Accumulated Other Comprehensive Income (Loss)

Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2015 were as follows:



	Gain (Loss) on Available for Sale Securities (1)						Defined Benefit Plans (2)						Foreign Currency Translation (3)						Total Accumulated Other Comprehensive Income (Loss)
	Three Months			Nine Months			Three Months			Nine Months			Three Months			Nine Months			Three Months			Nine Months
Beginning Balance	$	(332	)	$	1,068		$	7,760		$	(8,889	)	$	(66,891	)	$	(58,848	)	$	(59,463	)	$	(66,669	)
Other Comprehensive Income (Loss) before reclassifications	(147		)	(1,664		)	(837		)	32,100			(14,593		)	(22,636		)	(15,577		)	7,800
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	158			275			460			(15,828		)	—			—			618			(15,553		)
Net current-period Other Comprehensive Income (Loss)	11			(1,389		)	(377		)	16,272			(14,593		)	(22,636		)	(14,959		)	(7,753		)
Balance at December 31, 2015	$	(321	)	$	(321	)	$	7,383		$	7,383		$	(81,484	)	$	(81,484	)	$	(74,422	)	$	(74,422	)

Details of amounts reclassified from Accumulated Other Comprehensive Income (Loss) are as follows:

(1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income.

(2) Amortization (gain) and settlement of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income.

(3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment

9 Months Ended

Dec. 31, 2015

Property, Plant and Equipment

Information related to the major categories of our depreciable assets is as follows:



	December 31, 2015			March 31, 2015
Land and land improvements (1)	$	38,723		$	40,668
Buildings and leasehold improvements	440,504			263,007
Machinery and equipment	567,633			375,555
Information systems	121,944			104,049
Radioisotope	431,697			289,778
Linens (2)	41,552			—
Construction in progress (1)	87,661			47,690
Total property, plant, and equipment	1,729,714			1,120,747
Less: accumulated depreciation and depletion	(676,582		)	(627,694		)
Property, plant, and equipment, net	$	1,053,132		$	493,053


(1)	Land is not depreciated. Construction in progress is not depreciated until placed in service.


(2)	Linen was acquired as part of our combination with Synergy and is depreciated over useful lives ranging from one to five years.

Asset Retirement Obligations

We provide contract sterilization services including gamma irradiation which utilizes cobalt-60 in the form of cobalt pencils. We have incurred asset retirement obligations (ARO) associated with the disposal of these depleted assets. Recognition of ARO includes: the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and the periodic review of the ARO liability estimates and discount rates used in the analysis.

The following table summarizes the activity in the liability for asset retirement obligations.



	Asset Retirement Obligations
Balance at March 31, 2015	$	8,083
Liabilities assumed as result of combination with Synergy	8,686
Liabilities incurred during the period	43
Accretion expense	669
Foreign currency movement	$	(79	)
Balance at December 31, 2015	$	17,402

Inventories, Net

9 Months Ended

Dec. 31, 2015

Inventories, Net

Inventories, net are stated at the lower of cost or market. We use the last-in, first-out (“LIFO”) and first-in, first-out cost methods. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:



	December 31, 2015			March 31, 2015
Raw materials	$	63,662		$	67,095
Work in process	20,742			22,696
Finished goods	160,873			107,695
LIFO reserve	(17,972		)	(19,071		)
Reserve for excess and obsolete inventory	(18,999		)	(17,597		)
Inventories, net	$	208,306		$	160,818

Debt

9 Months Ended

Dec. 31, 2015

Debt

Indebtedness was as follows:



	December 31, 2015		March 31, 2015
Private Placement	$	662,460	$	337,825
Credit Agreement	977,001		283,250
Total long term debt	$	1,639,461	$	621,075

In order to fund the acquisition of Synergy, including the cash payments made in respect of Synergy shares, the repayment of Synergy debt and certain transaction expenses, STERIS plc borrowed (i) $132 million, £49 million, and €127.75 million under the Credit Agreement's revolving credit facility and (ii) $400 million under the Credit Agreement’s term loan facility on November 2, 2015. Borrowings bear interest at the Company’s option based upon either the Base Rate or the Eurocurrency Rate, plus the Applicable Margin in effect from time to time under the Credit Agreement. The Applicable Margin is determined based on the ratio of Consolidated Total Debt to Consolidated EBITDA. Interest on Base Rate Advances is payable quarterly in arrears and interest on Eurocurrency Rate Advances is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months.

Additional information regarding our indebtedness is included in the notes to Old STERIS's consolidated financial statements included in Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, dated August 7, 2015, and Annual Report on Form 10-K for the year ended March 31, 2015, dated May 27, 2015.

Additional Consolidated Balance Sheets Information

9 Months Ended

Dec. 31, 2015

Additional Consolidated Balance Sheets Information

Additional Consolidated Balance Sheet Information

Additional information related to our Consolidated Balance Sheets is as follows:



	December 31, 2015		March 31, 2015
Accrued payroll and other related liabilities:
Compensation and related items	$	35,173	$	16,680
Accrued vacation/paid time off	13,543		5,539
Accrued bonuses	26,626		30,159
Accrued employee commissions	11,557		12,842
Accrued pension	—		6,186
Other postretirement benefit obligations-current portion	2,790		2,789
Other employee benefit plans' obligations-current portion	1,278		610
Total accrued payroll and other related liabilities	$	90,967	$	74,805
Accrued expenses and other:
Deferred revenues	$	42,928	$	34,910
Self-insured risk reserves-current portion	8,017		6,897
Accrued dealer commissions	14,090		13,591
Accrued warranty	5,504		5,579
Asset retirement obligation-current portion	—		1,092
Other	82,128		39,963
Total accrued expenses and other	$	152,667	$	102,032
Other liabilities:
Self-insured risk reserves-long-term portion	$	12,052	$	12,052
Other postretirement benefit obligations-long-term portion	16,696		18,489
Defined benefit pension plans obligations-long-term portion	23,709		119
Other employee benefit plans obligations-long-term portion	5,570		6,634
Asset retirement obligation-long-term portion	17,402		6,991
Other	9,264		3,049
Total other liabilities	$	84,693	$	47,334

Income Tax Expense (Benefit)	9 Months Ended
Income Tax Expense (Benefit)	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Income Tax Expense (Benefit)	Income Tax Expense Income tax expense includes United States federal, state and local, and foreign income taxes, and is based on reported pre-tax income. The effective income tax rates for the three-month periods ended December 31, 2015 and 2014 were 28.1% and 33.0%, respectively. The effective income tax rates for the nine-month periods ended December 31, 2015 and 2014 were 35.6% and 35.5%, respectively. During the first nine months of fiscal 2016 we were unfavorably impacted by acquisition costs. However, this impact was offset by our re-domiciliation in the third quarter and discrete item adjustments. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. As of December 31, 2015, we have reserved for unrecognized tax benefits of $5,521 resulting from our Combination with Synergy. This balance is preliminary and the finalization of this amount may result in upward or downward purchase price allocation. Also at December 31, 2015, we have not recorded any liability for interest and penalties. As of March 31, 2015 we had no unrecognized tax benefits and have not recorded any liability for interest and penalties. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local authorities, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2014 and, with limited exceptions, we are no longer subject to United States state and local or non-United States income tax examinations by tax authorities for years before fiscal 2011. We remain subject to tax authority audits in various jurisdictions wherever we do business. We do not expect the results of these examinations to have a material adverse effect on our consolidated financial statements.

Benefit Plans

9 Months Ended

Dec. 31, 2015

Benefit Plans

In the United States we sponsor an unfunded postretirement welfare benefits plan for two groups of former employees. Benefits under this plan include retiree life insurance and retiree medical coverage, including prescription drug coverage.

In July 2014, the Board of Directors of American Sterilizer Company (“AMSCO”) approved the termination of the American Sterilizer Company Retirement Income Plan (“Plan”) effective October 1, 2014. The Pension Benefit Guaranty Corporation ("PBGC") did not object to this termination and AMSCO received a favorable determination from the IRS regarding the termination. On August 19, 2015, an annuity contract was purchased from Massachusetts Mutual Life Insurance Company to provide Plan benefits. Plan assets were converted to cash to fund the purchase. The purchase price of the annuity contract was $51,805. An additional employer contribution of $4,641 was made to the Plan to fund the annuity purchase obligation on August 26, 2015. As a result the purchase of the annuity, we recognized a pension settlement of $26,470. In addition, plan benefits and benefit administration became the responsibility of the annuity provider. The assumptions used to measure the benefit obligation as of March 31, 2015 reflected this effort. Additional information regarding this defined benefit pension plan and other postretirement benefits plan is included in our consolidated financial statements included in Old STERIS’s Annual Report on Form 10-K for the year ended March 31, 2015, dated May 27, 2015.

In addition, as a result of the combination with Synergy, we participate in seven defined benefit pension schemes outside the United States: three in the UK, one in the Netherlands, two in Germany, and one in Switzerland. Preliminarily estimated unfunded obligations of $23,507 were recorded as of the November 2, 2015 closing date of the Combination.

In the United Kingdom, we sponsor schemes which are funded defined benefit arrangements. Each has a separate trustee administered fund holding the pension scheme assets to meet long-term pension liabilities for past and present employees. The level of retirement benefit is principally based on the final pensionable salary prior to leaving active service, and is linked to changes in inflation up to retirement. The three UK schemes are as follows:

Synergy Health plc Retirement Benefits Scheme: The scheme is a defined benefit (final salary) funded pension scheme. Participation in this scheme is only offered to employees transferring their employment from National Health Service Trusts.

Shiloh Group Pension Scheme: The scheme is a defined benefit (final salary) funded pension scheme, which is closed to new members and which ceased accrual of benefits on March 31, 2011.

Vernon-Carus Limited Pension and Assurance Scheme: The scheme is a defined benefit (final salary) funded pension scheme, which is closed to new members and which ceased accrual of benefits on March 31, 2011.

In previous years, Synergy sponsored a funded defined benefit arrangement in the Netherlands. This was a separate fund holding the pension scheme assets to meet long term pension liabilities for past and present employees. Accrual of benefits ceased under the scheme effective January 1, 2013.

The Synergy Radeberg and Synergy Alleshausen Schemes are German defined benefit funded pension schemes which are closed to new entrants.

The Synergy Daniken Scheme is a Swiss defined benefit funded pension scheme.

Components of the net periodic benefit cost for our defined benefit pension plans and other postretirement medical benefits plan were as follows:



	AMSCO Plan					Other Defined Benefit Pension Plans					Other Postretirement Benefits Plan
	AMSCO Plan					Other Defined Benefit Pension Plans					Other Postretirement Benefits Plan
Three Months Ended December 31,	2015		2014			2015			2014		2015			2014
Service cost	$	—	$	35		$	324		$	—	$	—		$	—
Interest cost	—		471			641			—		148			173
Expected return on plan assets	—		(785		)	(506		)	—		—			—
Amortization of loss	—		277			—			—		207			180
Settlement	—		—			—			—		—			—
Amortization of prior service cost	—		—			—			—		(815		)	(816		)
Net periodic benefit cost	$	—	$	(2	)	$	459		$	—	$	(460	)	$	(463	)



	AMSCO Plan						Other Defined Benefit Pension Plans					Other Postretirement Benefits Plan
	AMSCO Plan						Other Defined Benefit Pension Plans					Other Postretirement Benefits Plan
Nine Months Ended December 31,	2015			2014			2015			2014		2015			2014
Service cost	$	27		$	105		$	324		—		—			—
Interest cost	560			1,415			641			—		444			518
Expected return on plan assets	(1,008		)	(2,355		)	(506		)	—		—			—
Amortization of loss	602			830			—			—		621			541
Settlement	26,515			—			—			—		—			—
Amortization of prior service cost	—			—			—			—		(2,445		)	(2,447		)
Net periodic benefit cost	$	26,696		$	(5	)	$	459		$	—	$	(1,380	)	$	(1,388	)

We contribute amounts to the defined benefit pension plans at least sufficient to meet the minimum requirements as stated in applicable employee benefit laws and local tax laws. The United Kingdom schemes are subject to the funding legislation outlined in the Pensions Act 2004 of the United Kingdom. This, together with documents issued by the UK Pensions Regulator, and Guidance Notes adopted by the Financial Reporting Council, set out the framework for funding defined benefit occupational pension schemes in the United Kingdom. The trustees of the schemes are required to act in the best interest of the schemes’ beneficiaries. The appointment of the trustees is determined by the schemes’ trust documentation.

We record liabilities for the difference between the fair value of the plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated postretirement benefit obligation for other postretirement benefits plans) on our accompanying condensed Consolidated Balance Sheets.

Finally, the Dutch linen business acquired in the Synergy combination participates in a multi-employer industry-wide defined benefit scheme. Participation in this pension plan is mandatory. The pension scheme is an average pay scheme with a conditional fee (indexation). Indexation of the assets and liabilities granted under the pension scheme takes place only if and insofar as the resources of the fund allow for it and this decision is taken by the pension fund. The pension entitlements under the pension plan are fully reinsured. It is not possible to identify the share of the underlying assets, liabilities, and overall surplus/deficit of the scheme attributable to the business, because the scheme is industry-wide. Under the guidance provided in ASC 715, "Compensation-Retirement Benefits", the scheme is treated as a defined contribution scheme within our financial statements. The total cost charged to the income statement in respect of this scheme was $459 for the three-month and nine-month periods ended December 31, 2015.

Contingencies	9 Months Ended
Contingencies	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Contingency [Text Block]	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results. On December 19, 2014, a purported shareholder of Old STERIS filed a Verified Stockholder Derivative Complaint in the Court of Common Pleas, Cuyahoga County, Ohio (the “Court”), against the members of Old STERIS’s board of directors and certain officers of Old STERIS, challenging the excise tax make-whole payments approved by Old STERIS’s board of directors in connection with the Combination. Old STERIS was named as a nominal defendant in the action. The case is captioned St. Lucie County Fire District Firefighters’ Pension Trust Fund v. Rosebrough, Jr., et al., Case No. CV 14 837749 (the “Action”). On September 28, 2015, the defendants reached an agreement in principle with plaintiff, regarding a settlement of the Action, and that agreement is reflected in a memorandum of understanding. In connection with the contemplated settlement, Old STERIS agreed to make certain additional disclosures related to the make-whole payments, which disclosures were reported on Old STERIS’s Form 8-K dated September 28, 2015, and also agreed not to grant any new stock compensation subject to Section 4985 of the Internal Revenue Code to any of the individual defendants in the Action until six months following the closing date of the Combination. The memorandum of understanding contemplates that the parties will enter into a stipulation of settlement, which will be subject to customary conditions, including the approval of the Court. In addition, in connection with the settlement, the parties have agreed to negotiate in good faith regarding the amount of attorneys’ fees and expenses that shall be paid to plaintiff’s counsel in connection with the Action. There can be no assurance that the parties will ultimately enter into a stipulation of settlement or that the Court will approve any stipulation of settlement. In such event, the proposed settlement as contemplated by the memorandum of understanding may be terminated. On July 8, 2015, the United States District Court for the Northern District of Ohio issued an Order terminating the April 20, 2010 consent decree entered into by two Company employees and the United States. The consent decree related to U.S. Food and Drug Administration (FDA) allegations regarding the Company’s now discontinued SYSTEM 1^® liquid chemical sterilization system. As a result of the termination of the consent decree, the Company is no longer subject to any court order related to its FDA regulatory compliance. Other civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015: “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factor” titled “We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters, including the Consent Decree”. From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of the applicable statute of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. Additional information regarding our contingencies is included in Item 7 of Part II titled, “Management's Discussion and Analysis of Financial Conditions and Results of Operations,” of Old STERIS’s Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015, and in Item 1 of Part II of this Form 10-Q titled, “Legal Proceedings.”

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

Business Segment Information

9 Months Ended

Dec. 31, 2015

Business Segment Information

As a result of the Combination with Synergy, we have reassessed the organization of our business. We have concluded that we operate and report in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs.

Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables.

Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management.

Our Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities.

Our Applied Sterilization Technologies segment offers a contract sterilization and laboratory services for medical device and pharmaceutical Customers and others.

The accounting policies for reportable segments are the same as those for the consolidated Company. Management evaluates performance and allocates resources based on a segment operating income measure. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which result in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare Products segment is responsible for the management of all but two manufacturing facilities and uses standard cost to sell products to the other segments. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits. Segment operating income excludes certain adjustments which include acquisition related costs, amortization of acquired intangibles, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by excluding these items they gain better insight and greater transparency of the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making.

For the three and nine month periods ended December 31, 2015, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in Old STERIS's consolidated financial statements included in its Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015.

Financial information for each of our reportable segments is presented in the following tables:



	Three Months Ended December 31,						Nine Months Ended December 31,
	2015			2014			2015			2014
Revenues:
Healthcare Products	$	317,060		$	287,515		$	872,028		$	823,957
Healthcare Specialty Services	128,326			65,682			264,974			183,219
Life Sciences	82,702			67,997			210,514			185,759
Applied Sterilization Technologies	90,225			50,960			199,753			154,003
Corporate and other	375			1,090			1,218			1,678
Total revenues	$	618,688		$	473,244		$	1,548,487		$	1,348,616
Segment operating income:
Healthcare Products	$	52,141		$	42,720		$	120,674		$	109,766
Healthcare Specialty Services	7,389			5,195			17,620			11,074
Life Sciences	24,115			16,482			58,448			41,615
Applied Sterilization Technologies	26,766			14,006			60,802			44,792
Corporate and other	(2,648		)	(1,406		)	(8,580		)	(5,310		)
Total segment operating income	$	107,763		$	76,997		$	248,964		$	201,937
Less: Adjustments
Restructuring charges (1)	$	(193	)	$	(1,076	)	$	(657	)	$	(427	)
Amortization of acquired intangible assets (2)	15,494			5,845			28,194			22,563
Acquisition and integration related charges (3)	41,726			10,860			77,254			17,556
Amortization of inventory and property "step up" to fair value (2)	4,060			22			4,102			1,310
Settlement of pension obligation (4)	(46		)	—			26,470			—
Loss on fair value of contingent consideration	—			—			—			1,998
Total operating income	$	46,722		$	61,346		$	113,601		$	158,937

(1) See Note 2 titled, "Restructuring" for more information related to restructuring.

(2) For more information regarding our recent acquisitions see Note 18 titled, "Business Acquisitions", as well as Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015, dated May 27, 2015.

(3) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

(4) See Note 8 titled, "Benefit Plans" for more information related to the settlement of the pension obligation.

Individual facilities, equipment, and intellectual properties are utilized for production by the Healthcare Products and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of these segments. Therefore, their respective amounts are reported together.



	December 31, 2015		March 31, 2015
Assets:
Healthcare Products and Life Sciences	$	1,684,872	$	1,261,940
Healthcare Specialty Services	753,396		396,579
Applied Sterilization Technologies	1,488,295		436,638
Total reportable segments	3,926,563		2,095,157
Corporate and other	2,521		2,134
Synergy related goodwill not yet allocated (1)	1,421,199		—
Total assets	$	5,350,283	$	2,097,291

(1) Amount is still preliminary as of December 31, 2015, as valuations have not been finalized. Goodwill will be allocated to the Healthcare Products, Healthcare Specialty Services and Applied Sterilization Technologies business segments.



	Nine months ended,
	December 31, 2015		December 31, 2014
Capital Expenditures:
Healthcare Products and Life Sciences	$	22,120	$	20,626
Healthcare Specialty Services	17,533		1,386
Applied Sterilization Technologies	42,457		34,731
Total Reportable Segments	82,110		56,743
Corporate and other	7		14
Total Capital Expenditures	$	82,117	$	56,757
Depreciation, Depletion, and Amortization:
Healthcare Products and Life Sciences	$	34,728	$	30,900
Healthcare Specialty Services	20,142		15,961
Applied Sterilization Technologies	35,999		22,552
Total Reportable Segments	90,869		69,413
Corporate and other	56		27
Total Depreciation, Depletion, and Amortization	$	90,925	$	69,440

Financial information for the United Kingdom, United States and other international countries is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant and equipment, net are those assets that are identified within the operations in each country or area.



	Three months ended December 31,				Nine months ended December 31,
	2015		2014		2015		2014
Revenues:
United Kingdom	$	51,468	$	13,421	$	73,382	$	38,225
United States	438,250		367,059		1,193,940		1,049,892
Other International	128,970		92,764		281,165		260,499
Total Revenues	$	618,688	$	473,244	$	1,548,487	$	1,348,616



	December 31, 2015		March 31, 2015
	2015		2015
Property, Plant, and Equipment, Net
United Kingdom	$	121,876	$	12,816
United States	506,916		441,278
Other International	424,340		38,959
Property, Plant, and Equipment, Net	$	1,053,132	$	493,053

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Shares and Preferred Shares

9 Months Ended

Dec. 31, 2015

Earnings Per Share [Text Block]

11. Shares and Preferred Shares

Common and Ordinary Shares

In connection with the Combination, each Old STERIS common shareholder received one ordinary share, par value 10 pence, of the Company for each Old STERIS common share held, and each Synergy ordinary shareholder received 0.4308 ordinary shares, par value 10 pence, of the Company and 439 pence in cash, for each Synergy ordinary share held.

We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:



	Three Months Ended December 31,		Nine Months Ended December 31,
	2015	2014	2015	2014
Denominator (shares in thousands):
Weighted average shares outstanding—basic	77,221	59,475	65,629	59,340
Dilutive effect of share equivalents	491	671	494	653
Weighted average shares outstanding and share equivalents—diluted	77,712	60,146	66,123	59,993

Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:



	Three Months Ended December 31,		Nine Months Ended December 31,
	2015	2014	2015	2014
(shares in thousands)
Number of share options	293	268	254	367

Preferred Shares

Pursuant to an engagement letter dated October 23, 2015, we issued 100,000 preferred shares, par value of £0.10 ($0.15) each, for an aggregate consideration of £10,000 or approximately $15, in satisfaction of debt owed to a service provider. The holders of the preferred shares are entitled to a fixed cumulative preferential annual dividend of 5 percent on the amount paid periodically on the preferred shares respectively held by them. On a return of capital of the Company whether on liquidation or otherwise, the holders of the preferred shares shall be entitled to receive out of the assets of the Company available for distribution to its shareholders the sum of £0.10 ($0.15) per preferred share plus any accrued but unpaid dividend, but will not be entitled to any further participation in the assets of the Company. The holders of the preferred shares will have no right to attend, speak or vote, whether in person or by proxy, at any general meeting of the Company or any meeting of a class of members of the Company in respect of the preferred shares and will not be entitled to receive any notice of meetings.

Repurchases of Common Shares	9 Months Ended
Repurchases of Common Shares	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Schedule of Treasury Stock by Class [Text Block]	Repurchases of Shares During the first nine months of fiscal 2016, we obtained 215,164 of our shares in connection with stock based compensation award programs.

Share-Based Compensation

9 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

We maintain a long-term incentive plan which we assumed from Old STERIS, that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. Prior to the Combination, awards were made in respect of common shares of Old STERIS. In conjunction with the Combination all outstanding common share denominated awards were converted into an equivalent number of Company ordinary share denominated awards, with the same terms and conditions as applied to the replaced awards.

Stock options provide the right to purchase our shares at the market price on the date of grant, subject to the terms of the option plans and agreements. Generally, one-fourth of the stock options granted become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally may cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each full year of employment after the grant date. As of December 31, 2015, 2,202,425 shares remained available for grant under the long-term incentive plan.

The fair value of share-based compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits.

The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2016 and fiscal 2015:



	Fiscal 2016		Fiscal 2015
Risk-free interest rate	1.51	%	1.89%
Expected life of options	5.69 years		5.75 years
Expected dividend yield of stock	1.40	%	1.87%
Expected volatility of stock	25.06	%	29.86%

The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of our historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 1.55% and 1.46% was applied in fiscal 2016 and 2015, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.

A summary of share option activity is as follows:



	Number of Options		Weighted Average Exercise Price		Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2015	1,759,890		$	37.03
Granted	366,700		66.88
Exercised	(337,982	)	32.25
Forfeited	(37,461	)	54.61
Canceled	(500	)	24.45
Outstanding at December 31, 2015	1,750,647		$	43.83	6.5 years	$	55,160
Exercisable at December 31, 2015	997,531		$	34.34	4.9 years	$	40,902

We estimate that 741,954 of the non-vested stock options outstanding at December 31, 2015 will ultimately vest.

The aggregate intrinsic value in the table above represents the total pre-tax difference between the $75.34 closing price of our ordinary shares on December 31, 2015 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our ordinary shares.

The total intrinsic value of stock options exercised during the first nine months of fiscal 2016 and fiscal 2015 was $12,221 and $22,289, respectively. Net cash proceeds from the exercise of stock options were $10,908 and $19,245 for the first nine months of fiscal 2016 and fiscal 2015, respectively. The tax benefit from shared-based compensation was $5,909 and $8,880 for the first nine months of fiscal 2016 and fiscal 2015, respectively.

The weighted average grant date fair value of stock option grants was $14.66 and $13.41 for the first nine months of fiscal 2016 and fiscal 2015, respectively.

Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of December 31, 2015 and 2014 was $2,527 and $2,073, respectively.

A summary of the non-vested restricted share activity is presented below:



	Number of Restricted Shares		Number of Restricted Share Units		Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2015	851,173		32,800		$	42.98
Granted	277,483		22,405		68.16
Vested	(205,453	)	(12,071	)	39.73
Canceled	(44,821	)	(1,493	)	49.84
Non-vested at December 31, 2015	878,382		41,641		$	51.61

Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares that vested during the first nine months of fiscal 2016 was $7,913.

Restricted share units carry generally the same terms and vesting requirements as restricted stock except that they may be settled in stock or cash upon vesting. Those that are settled in cash are classified as liabilities. All outstanding cash-settled restricted share units vested in the first quarter of fiscal 2016 and the only remaining outstanding restricted stock units are stock settled. The fair value of outstanding cash-settled restricted share units as of March 31, 2015 was $334. The fair value of each cash-settled restricted share unit is revalued at each reporting date and the related liability and expense are adjusted appropriately.

As of December 31, 2015, there was a total of $36,581 in unrecognized compensation cost related to nonvested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.3 years.

Financial and Other Guarantees

9 Months Ended

Dec. 31, 2015

Product Warranty Disclosure [Text Block]

Financial and Other Guarantees

We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.

Changes in our warranty liability during the first nine months of fiscal 2016 were as follows:




Balance, March 31, 2015	$	5,579
Warranties issued during the period	8,063
Settlements made during the period	(8,138		)
Balance, December 31, 2015	$	5,504

We also sell product maintenance contracts to our Customers. These contracts range in terms from one to five years and require us to maintain and repair the product over the maintenance contract term. We initially record amounts due from Customers under these contracts as a liability for deferred service contract revenue on the accompanying Consolidated Balance Sheets within “Accrued expenses and other.” The liability recorded for such deferred service revenue was $31,687 and $30,720 as of December 31, 2015 and March 31, 2015, respectively. Such deferred revenue is then amortized on a straight-line basis over the contract term and recognized as service revenue on our accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenues is excluded from the table presented above.

Derivatives and Hedging

9 Months Ended

Dec. 31, 2015

Derivative Instruments and Hedging Activities Disclosure [Text Block]

Derivatives and Hedging

From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2015, we held foreign currency forward contracts to buy 9 million Canadian dollars, 90 million Mexican pesos, and 4.5 million British pounds sterling. At December 31, 2015, we held commodity swap contracts to buy 181.2 thousand pounds of nickel.



	Asset Derivatives				Liability Derivatives
	Fair Value at		Fair Value at		Fair Value at		Fair Value at
Balance Sheet Location	December 31, 2015		March 31, 2015		December 31, 2015		March 31, 2015
Prepaid & Other	$	—	$	12	$	—	$	—
Accrued expenses and other	$	—	$	—	$	759	$	616

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:



	Location of gain (loss) recognized in income	Amount of gain (loss) recognized in income
		Three Months Ended December 31,						Nine Months Ended December 31,
		2015			2014			2015			2014
Foreign currency forward contracts	Selling, general and administrative	$	(380	)	$	(513	)	$	(642	)	$	(660	)
Commodity swap contracts	Cost of revenues	$	(159	)	$	(100	)	$	(491	)	$	214

Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $135,121 at December 31, 2015. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Fair Value Measurements

9 Months Ended

Dec. 31, 2015

Fair Value Disclosures [Text Block]

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at December 31, 2015 and March 31, 2015:



					Fair Value Measurements at December 31, 2015 and March 31, 2015 Using
	Carrying Value				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
					Level 1				Level 2				Level 3
	December 31		March 31		December 31		March 31		December 31		March 31		December 31		March 31
Assets:
Cash and cash equivalents (1)	$	231,360	$	167,689	$	207,525	$	148,944	$	23,835	$	18,745	$	—	$	—
Forward and swap contracts (2)	—		12		—		—		—		12		—		—
Investments (3)	7,579		8,332		7,579		8,332		—		—		—		—
Liabilities:
Forward and swap contracts (2)	$	759	$	616	$	—	$	—	$	759	$	616	$	—	$	—
Deferred compensation plans (3)	2,707		3,757		2,707		3,757		—		—		—		—
Long term debt (4)	1,639,461		621,075		—		—		1,642,034		641,131		—		—
Contingent consideration obligations (5)	4,557		2,500		—		—		—		—		4,557		2,500

(1) Money market fund holdings are classified as level two as active market quoted prices are not available.

(2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.

(3) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment.

(4) We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.

(5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2015 are summarized as follows:



	Contingent Consideration
Balance at March 31, 2015	$	2,500
Liabilities assumed as result of combination with Synergy	1,561
Additions	800
Payments	(122		)
Foreign currency translation adjustments (1)	(182		)
Balance at December 31, 2015	$	4,557

(1) Reported in other comprehensive income (loss).

Information regarding our investments is as follows:



					Investments at December 31, 2015 and March 31, 2015
	Cost				Unrealized Gains				Unrealized Losses (2)				Fair Value

	December 31		March 31		December 31		March 31		December 31		March 31		December 31		March 31
Available-for-sale securities:
Marketable equity securities (1)	$	4,681	$	4,681	$	252	$	—	$	—	$	—	$	4,933	$	4,681
Mutual funds	1,994		2,677		652		974		—		—		2,646		3,651
Total available-for-sale securities	$	6,675	$	7,358	$	904	$	974	$	—	$	—	$	7,579	$	8,332

(1) Our marketable equity securities have been in a unrealized loss position for less than 12 months.

(2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Business Combination Disclosure [Text Block]

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Restructuring (Notes)	9 Months Ended
Restructuring (Notes)	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring Fiscal 2014 Restructuring Plan. During the fourth quarter of fiscal 2014, Old STERIS adopted and announced a targeted restructuring plan primarily focused on the closure of its Hopkins manufacturing facility located in Mentor, Ohio (the “Fiscal 2014 Restructuring Plan”). As a result of this plan, operations located at Hopkins were transfered to other North American locations. We believe that by closing the operations at Hopkins we will more effectively utilize our existing North American manufacturing network while reducing operating costs. Since the inception of the Fiscal 2014 Restructuring Plan, we have incurred pre-tax expenses totaling $18,815 related to these actions, of which $10,720 was recorded as restructuring expenses and $8,095 was recorded in cost of revenues.We do not expect to incur any significant additional restructuring expenses related to this plan. These actions are intended to enhance profitability and improve efficiencies. Our total pre-tax restructuring expenses (credits) for the third quarter and first nine months of fiscal 2016 were ($193) and ($657), respectively. Our total pre-tax restructuring expenses (credits) for the third quarter and first nine months of fiscal 2015 were ($1,076) and ($427), respectively. Liabilities related to restructuring activities were $1,085 and $2,887 at December 31, 2015 and March 31, 2015, respectively. They are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.”

Business Acquisitions (Notes)

9 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Business Acquisitions

Synergy Health plc

On November 2, 2015, STERIS acquired all outstanding shares of Synergy in a cash and stock transaction valued at £24.80 ($38.17) per Synergy share, or a total of approximately $2.3 billion based on the low trading price of Old STERIS’s stock of $73.02 per share on November 2, 2015. The Combination brings together businesses that will generate revenues from over 60 countries, employ approximately 14,000 employees, and are geographically complementary. The Combination is expected to result in cost savings from optimizing global back-office infrastructure, leveraging best-demonstrated practices across plants, in-sourcing consumables, and eliminating redundant public company costs. Total costs of approximately $63,174 before tax, were incurred during the first nine months of fiscal year 2016 related to the Combination and are reported in selling, general and administrative expense.

Total consideration for the transaction is presented in the table below. At the closing date, vested share option awards remained outstanding under Synergy's Save As You Earn Plans ("SAYE"). In accordance with the provisions of SAYE, vested option awards may be exercised to the extent that the exercise price funds have been accumulated in accordance with the option holder's savings contract. The number of Synergy shares that are expected to be issued have been estimated and have been fair valued based on the same cash and stock consideration available to other Synergy shareholders at the time of the Combination.



Cash consideration	$	402,494
STERIS plc shares (25,848,798 ordinary shares estimated to be issued)	1,887,479
Fair value of consideration available to vested Synergy share option holders	3,626
Total purchase consideration	$	2,293,599

The acquisition of Synergy has been accounted for using the acquisition method of accounting which requires, among other things, the assets acquired and liabilities assumed be recognized at their respective fair values as of the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.

The entire purchase price allocation for Synergy is preliminary. As we finalize the fair value of assets acquired and liabilities assumed, additional purchase price adjustments will be recorded during the measurement period. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. The finalization of the purchase accounting assessment will result in changes in the valuation of assets acquired and liabilities assumed and may have a material impact on the our results of operations and financial position. Goodwill will be allocated to the Healthcare Products, Healthcare Specialty Services, and Applied Sterilization Technologies segments. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce, which are further described above. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.

Other Fiscal 2016 Acquisitions

On July 31, 2015 we acquired all of the outstanding shares of General Econopak, Inc. (“Gepco”) for a purchase price of $176,260 in cash, subject to a customary working capital adjustment. Gepco is a Pennsylvania-based manufacturer of product solutions in the areas of sterility maintenance, barrier protection, and sterile cleanroom products for pharmaceutical, biotechnology and veterinary Customers. Gepco is being integrated into our Life Sciences business segment. The purchase price was financed through a combination of credit facility borrowings and cash on hand. The allocation of premium to intangibles and goodwill is preliminary and will be finalized after the valuation reports are completed. We anticipate that the acquisition will qualify for joint election tax benefit under Section 338 (h)(10) of the Internal Revenue Code. We recorded $2,379 of acquisition related costs, which are reported in selling, general and administrative expense.

On June 12, 2015 we acquired the capital stock of Black Diamond Video, Inc. ("Black Diamond"), a California-based developer and provider of operating room integration systems. The purchase price was approximately $46,766, which includes deferred consideration of $5,870, to be paid approximately twelve months after the closing date, and contingent consideration of $800, and is subject to a working capital adjustment. The transaction consideration paid at closing was funded with cash on hand. Black Diamond is being integrated into our Healthcare Products business segment. The allocation of premium to intangibles and goodwill is preliminary and will be finalized after the valuation reports are completed.

We also completed several other minor purchases that continued to expand our service offerings in the Healthcare Products, Healthcare Specialty Services and Life Sciences segments. The aggregate purchase price associated with these transactions was approximately $41,344, including potential contingent consideration of $1,760.

The Consolidated Financial Statements include the operating results of these fiscal 2016 acquisitions from the acquisition dates. Pro-forma results of operations for the fiscal 2015 periods have not been presented because the effects of the acquisition were not material to our financial results. Acquisition related costs associated with fiscal 2016 acquisitions with the exception of Synergy and Gepco, have not been significant.

Fair Value of Assets Acquired and Liabilities Assumed

The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date. These preliminary estimates will be revised during the measurement period as third-party valuations are finalized, additional information becomes available and as additional analyzes are performed, and these differences could have a material impact on our results of operations and financial position.



	Synergy (1)			Gepco (1)			Black Diamond (1)			Other Acquisitions
Cash	$	53,057		$	1,108		$	—		$	—
Accounts receivable	104,666			4,161			2,966			3,859
Inventory	30,074			1,926			3,309			1,108
Property, plant and equipment	534,879			946			607			1,979
Other assets	19,708			1,621			43			—
Intangible assets	806,526			67,189			13,500			13,631
Goodwill	1,415,274			100,782			36,654			22,093
Total assets acquired	2,964,184			177,733			57,079			42,670
Current liabilities	(110,727		)	(1,473		)	(4,525		)	(1,277		)
Long-term indebtedness	(321,082		)	—			—			—
Other non-current liabilities	(230,020		)	—			(5,788		)	(49		)
Total liabilities assumed	(661,829		)	(1,473		)	(10,313		)	(1,326		)
Net assets acquired	$	2,302,355		$	176,260		$	46,766		$	41,344

(1) Purchase price allocation is still preliminary as of December 31, 2015, as valuations have not been finalized.

Intangible assets acquired in the Synergy acquisition consist of trade names, technology and Customer relationships. Preliminary values and useful lives are presented in the table below.



	Total (1)		Useful Live
Customer relationships	$	717,254	10-17 years
Trade names	64,645		10 years
Technology	24,627		7 years
Total intangible assets acquired	$	806,526

(1) Amounts are preliminary as of December 31, 2015, as valuations have not been finalized.

Contingent liabilities assumed as part of the Combination total $7,082 and are included within accrued expenses and other and other liabilities in the condensed consolidated balance sheet. These contingent liabilities include $5,521 related to income taxes (including uncertain tax positions) and $1,561 related to contingent consideration associated with prior acquisitions completed by Synergy. Contingent liabilities are recorded at their estimated fair values, aside from those pertaining to uncertainty in income taxes which are an exception to the fair value basis of accounting. See note 16, titled "Fair Value Measurements" to the condensed consolidated financial statements for additional information on contingent liabilities. The estimated fair values noted above are preliminary and are subject to change upon finalization of the purchase accounting assessment and may have a material impact on the our results of operations and financial position.

Actual and Pro Forma Impact

Our consolidated financial statements include Synergy's results of operations from the date of acquisition on November 2, 2015 through December 31, 2015. Net sales and operating income (loss) attributable to Synergy during this period and included in our consolidated financial statements for the three and nine month periods ended December 31, 2015 total $103,052 and $(1,659), respectively.

The following unaudited pro forma information gives effect to our acquisition of Synergy as if the acquisition had occurred on April 1, 2014 and Synergy had been included in our consolidated results of operations for the three and nine month periods ended December 31, 2015 and December 31, 2014.



	Three Months Ended December 31,				Nine Months Ended December 31,
	(unaudited)				(unaudited)
	2015		2014		2015		2014
Net revenues	$	681,254	$	638,857	$	1,928,779	$	1,831,740
Net income from continuing operations	45,910		39,406		118,388		111,046

The historical consolidated financial information of STERIS and Synergy has been adjusted in the pro forma information to give effect to pro forma events that are (1) directly attributable to the transaction, (2) factually supportable and (3) expected to have a continuing impact on the combined results. In order to reflect the occurrence of the acquisition on April 1, 2014 as required, the unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up, the incremental depreciation from the fair value adjustments to property, plant and equipment, and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets acquired. Adjustments to financing costs and income tax expense also were made to reflect the capital structure and anticipated effective tax rate of the combined entity. These pro forma amounts are not necessarily indicative of the results that would have been obtained if the acquisition had occurred as of the beginning of the period presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings.

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Related Party Transactions (Notes)	9 Months Ended
Related Party Transactions (Notes)	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Related Party Transactions Disclosure [Text Block]	19. Related Party Transactions On October 26, 2015, in connection with the consummation of the Combination, Dr. Richard Steeves, Group Executive Officer and Director of Synergy, elected to exercise employee stock options and hold the resulting Synergy shares. This exercise created an obligation on the part of Dr. Steeves totaling £3.1 million for income taxes and United Kingdom National Insurance contributions to be remitted by Synergy on his behalf, as well as the option exercise price. Synergy’s past practice, when requested by the employee who elected to exercise stock options and hold the resulting shares, was to pay income taxes and U.K. National Insurance contributions when due and obtain reimbursement from the employee for such taxes and the option exercise price within 90 days from the date of remittance. Upon completion of the Combination on November 2, 2015, Dr. Steeves ceased to be the Group Executive Officer and a Director of Synergy and became a non-executive Director of STERIS plc. Pursuant to the terms of the Combination, Dr. Steeves received STERIS plc shares and cash proceeds on November 6, 2015 in exchange for his Synergy equity holdings. The amount of the cash proceeds was £1.25 million, which was retained by Synergy and applied to his obligation, thereby reducing it to £1.86 million. Synergy remitted the £3.1 million of income taxes and U.K. National Insurance contributions to the appropriate United Kingdom agencies on November 20, 2015. Dr. Steeves remitted the balance of £1.86 million to Synergy on January 27, 2016 in satisfaction of his obligation to reimburse Synergy for the sums remitted by Synergy on his behalf. The arrangement between Dr. Steeves and Synergy effectively created a receivable that, under U.S. GAAP, was considered a loan. Loans by a public company to its executive officers and directors are prohibited under the Sarbanes-Oxley Act of 2002 and are also prohibited by the Company’s corporate governance policies and procedures. STERIS Corporation was not aware at the time of the closing of the Combination that Synergy had agreed to defer to a later date Dr. Steeves's obligation to reimburse the income taxes and U.K. National Insurance contributions and the option exercise price. Senior management learned of the arrangement when it was identified in the Company’s quarterly internal controls processes. Prepaid expenses and other current assets in the Company’s consolidated balance sheet includes the amount outstanding from Dr. Steeves, as well as a further amount due from another Synergy employee who also elected to exercise and hold Synergy shares immediately prior to the completion of the Combination. The other employee is neither an executive officer nor director of the Company. This additional amount was $368, which resulted in total receivables for both option exercises of $5,152 and $3,117 as of the November 2, 2015 acquisition date and December 31, 2015, respectively. The December 31, 2015 balances were remitted to Synergy in January 2016 and as a result of the repayments, no such amounts remain outstanding.

Quarterly Financial Information Disclosure [Abstract]

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Nature of Operations and Summary of Significant Accounting Policies Policies (Policies)

9 Months Ended

Dec. 31, 2015

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Recently issued accounting standards impacting the Company are presented in the following table:



Standard	Date of Issuance	Description	Date of Adoption	Effect on the financial statements or other significant matters
Standards that have recently been adopted
ASU 2015-16, "Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments"	September 2015	The standard requires the recognition of adjustments to provisional amounts, that are identified during the measurement period, in the reporting period in which the adjustments are determined. The effects of the adjustments to provisional amounts on depreciation, amortization or other income effects should be recognized in current-period earnings as if the accounting had been completed at the acquisition date. Disclosure of the portion of the adjustment recorded in current-period earnings that would have been reported in prior reporting periods if the adjustment to the provisional amounts had been recognized at the acquisition date is also required.	Third Quarter Fiscal 2016	This update did not have a material impact on our consolidated financial position, results of operations or cash flows.
ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs"	April 2015	The update requires capitalized debt issuance costs to be presented as a reduction to the carrying value of debt instead of being classified as a deferred charge, as previously required. This update is effective for all annual and interim periods beginning after December 15, 2015 and is required to be adopted retroactively for all periods presented. Early adoption was permitted.	First Quarter Fiscal 2016	This update did not have a material impact on our consolidated financial position, results of operations or cash flows.
Standards that have not yet been adopted
ASU 2014-09, "Revenue from Contracts with Customers"	May 2014	The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is not permitted before the original public entity effective date of December 15, 2016.	N/A	We are currently in the process of evaluating the impact that the standard will have on our consolidated financial position, results of operations and cash flows.



ASU 2015-05, "Goodwill and other - Internal-Use Software" (Subtopic 350-40)	April 2015	The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted.	N/A	We are currently in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.
ASU 2015-17, "Income Taxes Balance Sheet Classification of Deferred Taxes" (Topic 740)	November 2015	The update will require all entities that present a classified statement of financial position classify all deferred tax liabilities and assets as noncurrent in the statement. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount will not be affected by the Update.The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted.	N/A	We are currently in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.

Reclassifications out of AOCI (Tables)

9 Months Ended

Dec. 31, 2015

Reclassifications out of AOCI [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2015 were as follows:



	Gain (Loss) on Available for Sale Securities (1)						Defined Benefit Plans (2)						Foreign Currency Translation (3)						Total Accumulated Other Comprehensive Income (Loss)
	Three Months			Nine Months			Three Months			Nine Months			Three Months			Nine Months			Three Months			Nine Months
Beginning Balance	$	(332	)	$	1,068		$	7,760		$	(8,889	)	$	(66,891	)	$	(58,848	)	$	(59,463	)	$	(66,669	)
Other Comprehensive Income (Loss) before reclassifications	(147		)	(1,664		)	(837		)	32,100			(14,593		)	(22,636		)	(15,577		)	7,800
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	158			275			460			(15,828		)	—			—			618			(15,553		)
Net current-period Other Comprehensive Income (Loss)	11			(1,389		)	(377		)	16,272			(14,593		)	(22,636		)	(14,959		)	(7,753		)
Balance at December 31, 2015	$	(321	)	$	(321	)	$	7,383		$	7,383		$	(81,484	)	$	(81,484	)	$	(74,422	)	$	(74,422	)

Details of amounts reclassified from Accumulated Other Comprehensive Income (Loss) are as follows:

(1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income.

(2) Amortization (gain) and settlement of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income.

Property, Plant and Equipment Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Table Text Block]

Information related to the major categories of our depreciable assets is as follows:



	December 31, 2015			March 31, 2015
Land and land improvements (1)	$	38,723		$	40,668
Buildings and leasehold improvements	440,504			263,007
Machinery and equipment	567,633			375,555
Information systems	121,944			104,049
Radioisotope	431,697			289,778
Linens (2)	41,552			—
Construction in progress (1)	87,661			47,690
Total property, plant, and equipment	1,729,714			1,120,747
Less: accumulated depreciation and depletion	(676,582		)	(627,694		)
Property, plant, and equipment, net	$	1,053,132		$	493,053


(1)	Land is not depreciated. Construction in progress is not depreciated until placed in service.


(2)	Linen was acquired as part of our combination with Synergy and is depreciated over useful lives ranging from one to five years.

Asset Retirement Obligations [Table Text Block]



	Asset Retirement Obligations
Balance at March 31, 2015	$	8,083
Liabilities assumed as result of combination with Synergy	8,686
Liabilities incurred during the period	43
Accretion expense	669
Foreign currency movement	$	(79	)
Balance at December 31, 2015	$	17,402

Inventories, Net Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Schedule of Inventory, Current [Table Text Block]

Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:



	December 31, 2015			March 31, 2015
Raw materials	$	63,662		$	67,095
Work in process	20,742			22,696
Finished goods	160,873			107,695
LIFO reserve	(17,972		)	(19,071		)
Reserve for excess and obsolete inventory	(18,999		)	(17,597		)
Inventories, net	$	208,306		$	160,818

Additional Consolidated Balance Sheets Information Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Schedule of Accrued Liabilities [Table Text Block]

Additional information related to our Consolidated Balance Sheets is as follows:



	December 31, 2015		March 31, 2015
Accrued payroll and other related liabilities:
Compensation and related items	$	35,173	$	16,680
Accrued vacation/paid time off	13,543		5,539
Accrued bonuses	26,626		30,159
Accrued employee commissions	11,557		12,842
Accrued pension	—		6,186
Other postretirement benefit obligations-current portion	2,790		2,789
Other employee benefit plans' obligations-current portion	1,278		610
Total accrued payroll and other related liabilities	$	90,967	$	74,805
Accrued expenses and other:
Deferred revenues	$	42,928	$	34,910
Self-insured risk reserves-current portion	8,017		6,897
Accrued dealer commissions	14,090		13,591
Accrued warranty	5,504		5,579
Asset retirement obligation-current portion	—		1,092
Other	82,128		39,963
Total accrued expenses and other	$	152,667	$	102,032
Other liabilities:
Self-insured risk reserves-long-term portion	$	12,052	$	12,052
Other postretirement benefit obligations-long-term portion	16,696		18,489
Defined benefit pension plans obligations-long-term portion	23,709		119
Other employee benefit plans obligations-long-term portion	5,570		6,634
Asset retirement obligation-long-term portion	17,402		6,991
Other	9,264		3,049
Total other liabilities	$	84,693	$	47,334

Benefit Plans Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Defined Benefit Plan Disclosure [Line Items]

Schedule of Defined Benefit Plans Disclosures [Table Text Block]

Components of the net periodic benefit cost for our defined benefit pension plans and other postretirement medical benefits plan were as follows:



	AMSCO Plan					Other Defined Benefit Pension Plans					Other Postretirement Benefits Plan
	AMSCO Plan					Other Defined Benefit Pension Plans					Other Postretirement Benefits Plan
Three Months Ended December 31,	2015		2014			2015			2014		2015			2014
Service cost	$	—	$	35		$	324		$	—	$	—		$	—
Interest cost	—		471			641			—		148			173
Expected return on plan assets	—		(785		)	(506		)	—		—			—
Amortization of loss	—		277			—			—		207			180
Settlement	—		—			—			—		—			—
Amortization of prior service cost	—		—			—			—		(815		)	(816		)
Net periodic benefit cost	$	—	$	(2	)	$	459		$	—	$	(460	)	$	(463	)



	AMSCO Plan						Other Defined Benefit Pension Plans					Other Postretirement Benefits Plan
	AMSCO Plan						Other Defined Benefit Pension Plans					Other Postretirement Benefits Plan
Nine Months Ended December 31,	2015			2014			2015			2014		2015			2014
Service cost	$	27		$	105		$	324		—		—			—
Interest cost	560			1,415			641			—		444			518
Expected return on plan assets	(1,008		)	(2,355		)	(506		)	—		—			—
Amortization of loss	602			830			—			—		621			541
Settlement	26,515			—			—			—		—			—
Amortization of prior service cost	—			—			—			—		(2,445		)	(2,447		)
Net periodic benefit cost	$	26,696		$	(5	)	$	459		$	—	$	(1,380	)	$	(1,388	)

Business Segment Information Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]



	Three months ended December 31,				Nine months ended December 31,
	2015		2014		2015		2014
Revenues:
United Kingdom	$	51,468	$	13,421	$	73,382	$	38,225
United States	438,250		367,059		1,193,940		1,049,892
Other International	128,970		92,764		281,165		260,499
Total Revenues	$	618,688	$	473,244	$	1,548,487	$	1,348,616

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Business Segment Information

Our Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities.

Our Applied Sterilization Technologies segment offers a contract sterilization and laboratory services for medical device and pharmaceutical Customers and others.

Financial information for each of our reportable segments is presented in the following tables:



	Three Months Ended December 31,						Nine Months Ended December 31,
	2015			2014			2015			2014
Revenues:
Healthcare Products	$	317,060		$	287,515		$	872,028		$	823,957
Healthcare Specialty Services	128,326			65,682			264,974			183,219
Life Sciences	82,702			67,997			210,514			185,759
Applied Sterilization Technologies	90,225			50,960			199,753			154,003
Corporate and other	375			1,090			1,218			1,678
Total revenues	$	618,688		$	473,244		$	1,548,487		$	1,348,616
Segment operating income:
Healthcare Products	$	52,141		$	42,720		$	120,674		$	109,766
Healthcare Specialty Services	7,389			5,195			17,620			11,074
Life Sciences	24,115			16,482			58,448			41,615
Applied Sterilization Technologies	26,766			14,006			60,802			44,792
Corporate and other	(2,648		)	(1,406		)	(8,580		)	(5,310		)
Total segment operating income	$	107,763		$	76,997		$	248,964		$	201,937
Less: Adjustments
Restructuring charges (1)	$	(193	)	$	(1,076	)	$	(657	)	$	(427	)
Amortization of acquired intangible assets (2)	15,494			5,845			28,194			22,563
Acquisition and integration related charges (3)	41,726			10,860			77,254			17,556
Amortization of inventory and property "step up" to fair value (2)	4,060			22			4,102			1,310
Settlement of pension obligation (4)	(46		)	—			26,470			—
Loss on fair value of contingent consideration	—			—			—			1,998
Total operating income	$	46,722		$	61,346		$	113,601		$	158,937

(1) See Note 2 titled, "Restructuring" for more information related to restructuring.

(3) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

(4) See Note 8 titled, "Benefit Plans" for more information related to the settlement of the pension obligation.



	December 31, 2015		March 31, 2015
Assets:
Healthcare Products and Life Sciences	$	1,684,872	$	1,261,940
Healthcare Specialty Services	753,396		396,579
Applied Sterilization Technologies	1,488,295		436,638
Total reportable segments	3,926,563		2,095,157
Corporate and other	2,521		2,134
Synergy related goodwill not yet allocated (1)	1,421,199		—
Total assets	$	5,350,283	$	2,097,291



	Nine months ended,
	December 31, 2015		December 31, 2014
Capital Expenditures:
Healthcare Products and Life Sciences	$	22,120	$	20,626
Healthcare Specialty Services	17,533		1,386
Applied Sterilization Technologies	42,457		34,731
Total Reportable Segments	82,110		56,743
Corporate and other	7		14
Total Capital Expenditures	$	82,117	$	56,757
Depreciation, Depletion, and Amortization:
Healthcare Products and Life Sciences	$	34,728	$	30,900
Healthcare Specialty Services	20,142		15,961
Applied Sterilization Technologies	35,999		22,552
Total Reportable Segments	90,869		69,413
Corporate and other	56		27
Total Depreciation, Depletion, and Amortization	$	90,925	$	69,440



	Three months ended December 31,				Nine months ended December 31,
	2015		2014		2015		2014
Revenues:
United Kingdom	$	51,468	$	13,421	$	73,382	$	38,225
United States	438,250		367,059		1,193,940		1,049,892
Other International	128,970		92,764		281,165		260,499
Total Revenues	$	618,688	$	473,244	$	1,548,487	$	1,348,616



	December 31, 2015		March 31, 2015
	2015		2015
Property, Plant, and Equipment, Net
United Kingdom	$	121,876	$	12,816
United States	506,916		441,278
Other International	424,340		38,959
Property, Plant, and Equipment, Net	$	1,053,132	$	493,053

Assets [Member]

Schedule of Segment Reporting Information, by Segment [Table Text Block]



	December 31, 2015		March 31, 2015
Assets:
Healthcare Products and Life Sciences	$	1,684,872	$	1,261,940
Healthcare Specialty Services	753,396		396,579
Applied Sterilization Technologies	1,488,295		436,638
Total reportable segments	3,926,563		2,095,157
Corporate and other	2,521		2,134
Synergy related goodwill not yet allocated (1)	1,421,199		—
Total assets	$	5,350,283	$	2,097,291

Other Expense [Member]

Schedule of Segment Reporting Information, by Segment [Table Text Block]



	Nine months ended,
	December 31, 2015		December 31, 2014
Capital Expenditures:
Healthcare Products and Life Sciences	$	22,120	$	20,626
Healthcare Specialty Services	17,533		1,386
Applied Sterilization Technologies	42,457		34,731
Total Reportable Segments	82,110		56,743
Corporate and other	7		14
Total Capital Expenditures	$	82,117	$	56,757
Depreciation, Depletion, and Amortization:
Healthcare Products and Life Sciences	$	34,728	$	30,900
Healthcare Specialty Services	20,142		15,961
Applied Sterilization Technologies	35,999		22,552
Total Reportable Segments	90,869		69,413
Corporate and other	56		27
Total Depreciation, Depletion, and Amortization	$	90,925	$	69,440

Shares and Preferred Shares Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Schedule of Weighted Average Number of Shares [Table Text Block]

The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:



	Three Months Ended December 31,		Nine Months Ended December 31,
	2015	2014	2015	2014
Denominator (shares in thousands):
Weighted average shares outstanding—basic	77,221	59,475	65,629	59,340
Dilutive effect of share equivalents	491	671	494	653
Weighted average shares outstanding and share equivalents—diluted	77,712	60,146	66,123	59,993

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]



	Three Months Ended December 31,		Nine Months Ended December 31,
	2015	2014	2015	2014
(shares in thousands)
Number of share options	293	268	254	367

Share-Based Compensation Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Assumptions Used

The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2016 and fiscal 2015:



	Fiscal 2016		Fiscal 2015
Risk-free interest rate	1.51	%	1.89%
Expected life of options	5.69 years		5.75 years
Expected dividend yield of stock	1.40	%	1.87%
Expected volatility of stock	25.06	%	29.86%

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding

A summary of share option activity is as follows:



	Number of Options		Weighted Average Exercise Price		Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2015	1,759,890		$	37.03
Granted	366,700		66.88
Exercised	(337,982	)	32.25
Forfeited	(37,461	)	54.61
Canceled	(500	)	24.45
Outstanding at December 31, 2015	1,750,647		$	43.83	6.5 years	$	55,160
Exercisable at December 31, 2015	997,531		$	34.34	4.9 years	$	40,902

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of the non-vested restricted share activity is presented below:



	Number of Restricted Shares		Number of Restricted Share Units		Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2015	851,173		32,800		$	42.98
Granted	277,483		22,405		68.16
Vested	(205,453	)	(12,071	)	39.73
Canceled	(44,821	)	(1,493	)	49.84
Non-vested at December 31, 2015	878,382		41,641		$	51.61

Financial and Other Guarantees Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Schedule of Guarantor Obligations [Table Text Block]

Changes in our warranty liability during the first nine months of fiscal 2016 were as follows:




Balance, March 31, 2015	$	5,579
Warranties issued during the period	8,063
Settlements made during the period	(8,138		)
Balance, December 31, 2015	$	5,504

Derivatives and Hedging Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]



	Asset Derivatives				Liability Derivatives
	Fair Value at		Fair Value at		Fair Value at		Fair Value at
Balance Sheet Location	December 31, 2015		March 31, 2015		December 31, 2015		March 31, 2015
Prepaid & Other	$	—	$	12	$	—	$	—
Accrued expenses and other	$	—	$	—	$	759	$	616

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:



	Location of gain (loss) recognized in income	Amount of gain (loss) recognized in income
		Three Months Ended December 31,						Nine Months Ended December 31,
		2015			2014			2015			2014
Foreign currency forward contracts	Selling, general and administrative	$	(380	)	$	(513	)	$	(642	)	$	(660	)
Commodity swap contracts	Cost of revenues	$	(159	)	$	(100	)	$	(491	)	$	214

Fair Value Measurements Level 3 (Tables)

9 Months Ended

Dec. 31, 2015

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value, Measurement Inputs, Disclosure [Table Text Block]

The following table shows the fair value of our financial assets and liabilities at December 31, 2015 and March 31, 2015:



					Fair Value Measurements at December 31, 2015 and March 31, 2015 Using
	Carrying Value				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
					Level 1				Level 2				Level 3
	December 31		March 31		December 31		March 31		December 31		March 31		December 31		March 31
Assets:
Cash and cash equivalents (1)	$	231,360	$	167,689	$	207,525	$	148,944	$	23,835	$	18,745	$	—	$	—
Forward and swap contracts (2)	—		12		—		—		—		12		—		—
Investments (3)	7,579		8,332		7,579		8,332		—		—		—		—
Liabilities:
Forward and swap contracts (2)	$	759	$	616	$	—	$	—	$	759	$	616	$	—	$	—
Deferred compensation plans (3)	2,707		3,757		2,707		3,757		—		—		—		—
Long term debt (4)	1,639,461		621,075		—		—		1,642,034		641,131		—		—
Contingent consideration obligations (5)	4,557		2,500		—		—		—		—		4,557		2,500

Fair Value, by Balance Sheet Grouping [Table Text Block]

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2015 are summarized as follows:



	Contingent Consideration
Balance at March 31, 2015	$	2,500
Liabilities assumed as result of combination with Synergy	1,561
Additions	800
Payments	(122		)
Foreign currency translation adjustments (1)	(182		)
Balance at December 31, 2015	$	4,557

(1) Reported in other comprehensive income (loss).

Unrealized Gain (Loss) on Investments [Table Text Block]

Information regarding our investments is as follows:



					Investments at December 31, 2015 and March 31, 2015
	Cost				Unrealized Gains				Unrealized Losses (2)				Fair Value

	December 31		March 31		December 31		March 31		December 31		March 31		December 31		March 31
Available-for-sale securities:
Marketable equity securities (1)	$	4,681	$	4,681	$	252	$	—	$	—	$	—	$	4,933	$	4,681
Mutual funds	1,994		2,677		652		974		—		—		2,646		3,651
Total available-for-sale securities	$	6,675	$	7,358	$	904	$	974	$	—	$	—	$	7,579	$	8,332

(1) Our marketable equity securities have been in a unrealized loss position for less than 12 months.

(2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Business Acquisitions (Tables)

9 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Business Acquisition, Pro Forma Information [Table Text Block]



	Three Months Ended December 31,				Nine Months Ended December 31,
	(unaudited)				(unaudited)
	2015		2014		2015		2014
Net revenues	$	681,254	$	638,857	$	1,928,779	$	1,831,740
Net income from continuing operations	45,910		39,406		118,388		111,046

Business Combination With Synergy Total Consideration [Table Text Block]



Cash consideration	$	402,494
STERIS plc shares (25,848,798 ordinary shares estimated to be issued)	1,887,479
Fair value of consideration available to vested Synergy share option holders	3,626
Total purchase consideration	$	2,293,599

Schedule of Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]



	Total (1)		Useful Live
Customer relationships	$	717,254	10-17 years
Trade names	64,645		10 years
Technology	24,627		7 years
Total intangible assets acquired	$	806,526

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

Purchase price allocation is still preliminary as of December 31, 2015, as valuations have not been finalized.



	Synergy (1)			Gepco (1)			Black Diamond (1)			Other Acquisitions
Cash	$	53,057		$	1,108		$	—		$	—
Accounts receivable	104,666			4,161			2,966			3,859
Inventory	30,074			1,926			3,309			1,108
Property, plant and equipment	534,879			946			607			1,979
Other assets	19,708			1,621			43			—
Intangible assets	806,526			67,189			13,500			13,631
Goodwill	1,415,274			100,782			36,654			22,093
Total assets acquired	2,964,184			177,733			57,079			42,670
Current liabilities	(110,727		)	(1,473		)	(4,525		)	(1,277		)
Long-term indebtedness	(321,082		)	—			—			—
Other non-current liabilities	(230,020		)	—			(5,788		)	(49		)
Total liabilities assumed	(661,829		)	(1,473		)	(10,313		)	(1,326		)
Net assets acquired	$	2,302,355		$	176,260		$	46,766		$	41,344

Reclassifications out of AOCI (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Sep. 30, 2015

Mar. 31, 2015

Accumulated Other Comprehensive Income (Loss), Net of Tax

$ (74,422)

$ (59,463)

$ (66,669)

Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax

$ (569)

(1,389)

$ (510)

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax

(14,593)

(18,806)

(22,636)

(35,497)

Other Comprehensive Income (Loss), Net of Tax

(15,577)

7,800

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

618

(15,553)

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

(14,959)

$ (19,597)

(7,753)

$ (36,672)

Accumulated Net Unrealized Investment Gain (Loss) [Member]

Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax

^[1]

(321)

(332)

1,068

Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax

^[1]

(147)

(1,664)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

^[1]

158

275

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

^[1]

(1,389)

Accumulated Defined Benefit Plans Adjustment [Member]

Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax

^[2]

7,383

7,760

(8,889)

Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax

^[2]

(837)

32,100

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

^[2]

460

(15,828)

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

^[2]

(377)

16,272

Accumulated Translation Adjustment [Member]

Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax

^[3]

(81,484)

$ (66,891)

$ (58,848)

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax

^[3]

(14,593)

(22,636)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

^[3]

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

^[3]

$ (14,593)

$ (22,636)

[1]	(1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income.
[2]	(2) Amortization (gain) and settlement of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income.
[3]	The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Property, Plant and Equipment Level 4 (Details) - USD ($)
$ in Thousands

9 Months Ended

Dec. 31, 2015

Mar. 31, 2015

Mar. 31, 2014

Property, Plant and Equipment [Line Items]

Asset Retirement Obligation

$ 17,402

$ 8,083

Asset Retirement Obligation, Foreign Currency Translation

(79)

Land

^[1]

38,723

$ 40,668

Buildings and Improvements, Gross

440,504

263,007

Machinery and Equipment, Gross

567,633

375,555

Capitalized Computer Software, Gross

121,944

104,049

Materials, Supplies, and Other

431,697

289,778

Linen

41,552

Construction in Progress, Gross

^[1]

87,661

47,690

Property, Plant and Equipment, Gross

1,729,714

1,120,747

Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment

(676,582)

(627,694)

Asset Retirement Obligation, Liabilities Incurred

1,053,132

$ 493,053

Asset Retirement Obligation, Accretion Expense

669

Property, Plant and Equipment [Line Items]

Asset Retirement Obligation, Liabilities Incurred

$ 8,686

[1]	Land is not depreciated. Construction in progress is not depreciated until placed in service.

Inventories, Net Level 4 (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Inventory, Raw Materials	$ 63,662	$ 67,095
Inventory, Work in Process	20,742	22,696
Inventory, Finished Goods	160,873	107,695
Inventory, LIFO Reserve	(17,972)	(19,071)
Inventory Valuation Reserves	(18,999)	(17,597)
Inventory, Net	$ 208,306	$ 160,818

Debt Level 4 (Details) € in Thousands, £ in Thousands, $ in Thousands	9 Months Ended
	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 GBP (£)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 EUR (€)	Mar. 31, 2015 USD ($)
Debt Instrument [Line Items]
Proceeds from Issuance of Private Placement	$ 350,000	$ 0
Debt Instrument, Face Amount				$ 662,460		$ 337,825
Long-term Line of Credit				977,001		283,250
Long-term Debt				1,639,461		$ 621,075
United States of America, Dollars
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding				132,000
United Kingdom, Pounds
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding \| £			£ 49,000
Euro Member Countries, Euro
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding \| €					€ 127,750
Term Loan Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding				$ 400,000

Additional Consolidated Balance Sheets Information Level 4 (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Employee-related Liabilities	$ 35,173	$ 16,680
Accrued Vacation	13,543	5,539
Accrued Bonuses	26,626	30,159
Accrued Liabilities for Commissions, Expense and Taxes	11,557	12,842
Defined Benefit Pension Plan, Liabilities	0	6,186
Other Postretirement Benefits Payable	2,790	2,789
Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities	1,278	610
Employee-related Liabilities, Current	90,967	74,805
Deferred Revenue	42,928	34,910
Self Insurance Reserve, Current	8,017	6,897
Accrued Sales Commission	14,090	13,591
Product Warranty Accrual	5,504	5,579
Asset Retirement Obligation, Current	0	1,092
Accrued Liabilities	152,667	102,032
Self Insurance Reserve, Noncurrent	12,052	12,052
Other Postretirement Benefits Payable, Noncurrent	16,696	18,489
Defined Benefit Pension Plan, Liabilities, Noncurrent	23,709	119
Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent	5,570	6,634
Accrued Income Taxes, Noncurrent	17,402	6,991
Other Liabilities	9,264	3,049
Other Accrued Liabilities	82,128	39,963
Other Liabilities, Noncurrent	$ 84,693	$ 47,334

Income Tax Expense Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Effective Income Tax Rate, Continuing Operations	28.10%	33.00%	35.60%	35.50%
Unrecognized Tax Benefits	$ 5,521		$ 5,521

Benefit Plans Level 4 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Benefit Plans Level 4 (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
DBP Purchase price of annuity contract					$ 51,805
Defined Benefit Plan, Contributions by Employer			$ 4,641
Defined Benefit Plan, Settlements, Benefit Obligation	$ 46	$ 0	26,470	$ 0
Preliminary Estimated Unfunded Benefit Obligation- Synergy Plans	23,507		23,507
United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	35	27	105
Defined Benefit Plan, Interest Cost	0	471	560	1,415
Defined Benefit Plan, Expected Return on Plan Assets	0	(785)	(1,008)	(2,355)
Defined Benefit Plan, Amortization of Gains (Losses)	0	277	602	830
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost	0	(2)	26,696	(5)
Defined Benefit Plan, Settlements, Benefit Obligation	0	0	26,515	0
Other Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	324	0	324	0
Defined Benefit Plan, Interest Cost	641	0	641	0
Defined Benefit Plan, Expected Return on Plan Assets	(506)	0	(506)	0
Defined Benefit Plan, Amortization of Gains (Losses)	0	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost	459	0	459	0
Defined Benefit Plan, Settlements, Benefit Obligation	0	0	0	0
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	0	0	0
Defined Benefit Plan, Interest Cost	148	173	444	518
Defined Benefit Plan, Expected Return on Plan Assets	0	0	0	0
Defined Benefit Plan, Amortization of Gains (Losses)	207	180	621	541
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(815)	(816)	(2,445)	(2,447)
Defined Benefit Plan, Net Periodic Benefit Cost	(460)	(463)	(1,380)	(1,388)
Defined Benefit Plan, Settlements, Benefit Obligation	$ 0	$ 0	$ 0	$ 0

Business Segment Information Level 4 (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

$ 82,117

$ 56,757

$ 1,053,132

1,053,132

$ 493,053

5,350,283

2,097,291

618,688

$ 473,244

1,548,487

1,348,616

Amortization of intangible assets acquired through acquisitions

46,722

61,346

113,601

158,937

Restructuring Charges

^[1]

(193)

(1,076)

(657)

(427)

Restructuring Costs

(194)

(1,109)

(976)

(10)

^[2]

15,494

5,845

28,194

22,563

Acquisition and integration related charges

^[3]

41,726

10,860

77,254

17,556

Amortization of inventory and property step up to fair value

^[2]

4,060

4,102

1,310

Defined Benefit Plan, Settlements, Benefit Obligation

(46)

(26,470)

Loss on fair value contingent consideration adjustment

1,998

Healthcare Products [Member] [Member]

90,925

69,440

22,120

20,626

317,060

287,515

872,028

823,957

52,141

42,720

120,674

109,766

Applied Sterilization Technologies [Member]

34,728

30,900

42,457

34,731

1,488,295

436,638

Corporate and Other [Member]

35,999

22,552

82,110

56,743

3,926,563

2,095,157

OperatingSegmentLifeSciences [Member]

90,869

69,413

82,702

67,997

210,514

185,759

24,115

16,482

58,448

41,615

AST [Member] [Member]

OperatingSegmentIsomedix [Member]

90,225

50,960

199,753

154,003

OperatingSegmentCorpandOther [Member]

26,766

14,006

60,802

44,792

375

1,090

1,218

1,678

OperatingSegmentAll [Member]

(2,648)

(1,406)

(8,580)

(5,310)

618,688

473,244

1,548,487

1,348,616

operating income by segment

46,722

61,346

113,601

158,937

107,763

76,997

248,964

201,937

Operating Segments [Member]

17,533

1,386

753,396

396,579

128,326

65,682

264,974

183,219

7,389

5,195

17,620

11,074

Corporate and Other member [Member]

20,142

15,961

2,521

2,134

United Kingdom [Member]

121,876

12,816

51,468

13,421

73,382

38,225

UNITED STATES

506,916

441,278

International Member [Member]

438,250

367,059

1,193,940

1,049,892

424,340

$ 38,959

$ 128,970

$ 92,764

$ 281,165

$ 260,499

[1]	See Note 2 titled, "Restructuring" for more information related to restructuring
[2]	For more information regarding our recent acquisitions see Note 18 titled, "Business Acquisitions", as well as Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015, dated May 27, 2015.
[3]	Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

Business Segment Information Details - Business Combinations (Details) - USD ($)
$ in Thousands

9 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Operating Segments [Member]

$ 5,350,283

$ 2,097,291

Pension Expense

26,470

$ 0

Applied Sterilization Technologies [Member]

753,396

396,579

Corporate and Other [Member]

1,488,295

436,638

Corporate and Other member [Member]

3,926,563

2,095,157

Healthcare Products [Member] [Member]

2,521

2,134

1,684,872

1,261,940

Goodwill, Not Allocated, Amount

^[1]

$ 1,421,199

$ 0

[1]	(1) Amount is still preliminary as of December 31, 2015, as valuations have not been finalized.

Shares and Preferred Shares Level 4 (Details) £ / shares in Units, $ / shares in Units, £ in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015 GBP (£) £ / shares shares	Dec. 31, 2014 shares	Dec. 31, 2015 GBP (£) £ / shares shares	Dec. 31, 2014 shares	Dec. 31, 2015 USD ($) $ / shares shares	Mar. 31, 2015 USD ($) $ / shares shares
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Ordinary Share par value in pence received by Old STERIS shareholders resulting from the Combination \| £ / shares	£ 0.10		£ 0.10
Cash value in pence by received by Synergy shareholder resulting from Combination	0.4308		0.4308		0.4308
Preferred Stock, Shares Issued	100,000		100,000		100,000	0
Preferred Stock, Redemption Price Per Share \| (per share)	£ 0.10		£ 0.10		$ 0.15
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding \| $ / shares					$ 0.15	$ 0.00
Weighted Average Number of Shares Outstanding, Basic	77,221,000	59,475,000	65,629,000	59,340,000
Weighted Average Number Diluted Shares Outstanding Adjustment	491,000	671,000	494,000	653,000
Weighted Average Number of Shares Outstanding, Diluted	77,712,000	60,146,000	66,123,000	59,993,000
Preferred shares, with £0.10 par value; 100,000 shares authorized; 100,000 issued and outstanding \| $					$ 15	$ 0
Preferred Stock, Dividend Rate, Percentage	5.00%
Ordinary Share par value in pence received by Synergy shareholders in exchange resulting from the Combination \| £ / shares	£ 0.10		£ 0.10
United Kingdom, Pounds
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding \| £ / shares	£ 0.10		£ 0.10
Preferred shares, with £0.10 par value; 100,000 shares authorized; 100,000 issued and outstanding \| £	£ 10		£ 10
United States of America, Dollars
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding \| $ / shares					$ 0.15
Preferred shares, with £0.10 par value; 100,000 shares authorized; 100,000 issued and outstanding \| $					$ 15

Shares and Preferred Shares Common share options (Details) shares in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015 £ / shares shares	Dec. 31, 2014 shares	Dec. 31, 2015 £ / shares shares	Dec. 31, 2014 shares	Dec. 31, 2015 $ / shares	Mar. 31, 2015 $ / shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary Share par value in pence received by Old STERIS shareholders resulting from the Combination	£ 0.10		£ 0.10
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding \| $ / shares					$ 0.15	$ 0.00
Ordinary Share par value in pence received by Synergy shareholders in exchange resulting from the Combination	£ 0.10		£ 0.10
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number \| shares	293	268	254	367

Repurchases of Common Shares Level 4 (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Treasury Stock, Shares, Acquired	0		10,364,404
Payments for Repurchase of Common Stock	$ 14,069	$ 20,110
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	215,164

Share-Based Compensation Level 4 (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2015 USD ($) £ / shares $ / shares shares	Dec. 31, 2014 USD ($) $ / shares	Dec. 31, 2015 USD ($)	Dec. 31, 2015 $ / shares	Dec. 31, 2015 shares	Dec. 31, 2015	Mar. 31, 2015 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Number of ordinary shares in STERIS plc stock received by Synergy shareholder in exchange	4.39					0.4308
Remaining shares available for grant					2,202,425
Weighted-average assumptions used for options granted:
Risk-free interest rate	1.51%	1.89%
Expected life of options	5 years 8 months 9 days	5 years 9 months
Exptected dividend yield of stock	1.40%	1.87%
Expected volatility of stock	25.06%	29.86%
Estimated forfeiture rate	1.55%	1.46%
Summary of share option activity:
Number of Options, Outstanding, Beginning of Period	1,759,890
Weighted Average Exercise Price, Outstanding, Beginning of Period \| $ / shares	$ 37.03
Number of Options, Granted	366,700
Weighted Average Exercise Price, Granted \| $ / shares	$ 66.88
Number of Options, Exercised	(337,982)
Weighted Average Exercise Price, Exercised \| $ / shares	$ 32.25
Number of Options, Forfeited	(37,461)
Weighted Average Exercise Price, Forfeited \| $ / shares	$ 54.61
Number of Options, Canceled	(500)
Weighted Average Exercise Price, Canceled \| $ / shares	$ 24.45
Number of Options, Outstanding, End of Period	1,750,647
Weighted Average Exercise Price, Outstanding, End of Period \| $ / shares	$ 43.83
Average Remaining Contractual Term, Outstanding	6 years 6 months
Aggregate Intrinsic Value, Outstanding \| $			$ 55,160
Number of Options, Exercisable					997,531
Weighted Average Exercise Price, Exercisable \| $ / shares				$ 34.34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 10 months 24 days
Aggregate Intrinsic Value, Exercisable \| $			40,902
Non-vested stock options outstanding expected to vest					741,954
Common Stock, Fair Market Value Per Share \| $ / shares				$ 75.34
Total intrinsic value of stock options exercised \| $	$ 12,221	$ 22,289
Net cash proceeds from the exercise of stock options \| $	10,908	19,245
Tax benefit from stock option exercises \| $	$ 5,909	$ 8,880
Weighted average grant date fair value of stock option grants, per share \| $ / shares	$ 14.66	$ 13.41
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted \| $			36,581
Weighted average period for recognition of unrecognized compensation cost	2 years 3 months 18 days
Stock Appreciation Rights (SARs) [Member]
Summary of non-vested restricted share activity:
FairValueOfOutstandingStockAppreciationRights \| $		$ 2,073	$ 2,527
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	851,173
Number of Restricted Shares, Granted	277,483
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares	$ 68.16
Number of Restricted Shares, Vested	(205,453)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value \| $ / shares	$ 39.73
Number of Restricted Shares, Canceled	(44,821)
Number of Restricted Shares, Non-vested at End of Period	878,382
Weighted-Average Grant Date Fair Value, Non-vested at End of Period \| $ / shares	$ 42.98
Weighted-Average Grant Date Fair Value, Non-vested at End of Period \| $ / shares	$ 51.61
Fair Value, Share-based Payment Awards, Other than Options \| $	$ 7,913
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value \| $ / shares	$ 49.84
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	32,800
Number of Restricted Shares, Granted	22,405
Number of Restricted Shares, Vested	(12,071)
Number of Restricted Shares, Canceled	(1,493)
Number of Restricted Shares, Non-vested at End of Period	41,641
FairValueOfOutstandingCashSettledRestrictedShareUnits \| $							$ 334

Financial and Other Guarantees Level 4 (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Guarantor Obligations [Line Items]
Product Warranty Accrual	$ 5,504	$ 5,579
Product Warranty Accrual, Warranties Issued	8,063
Standard Product Warranty Accrual, Payments	(8,138)
Service Agreements [Member]
Guarantor Obligations [Line Items]
Deferred Revenue, Current	$ 31,687	$ 30,720

Derivatives and Hedging Level 4 (Details) £ in Thousands, MXN in Thousands, CAD in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 MXN lb	Dec. 31, 2015 GBP (£) lb	Dec. 31, 2015 USD ($) lb	Dec. 31, 2015 CAD lb	Mar. 31, 2015 USD ($)
Derivative [Line Items]
Non-derivative Net Investment Hedge							$ 135,121
Other Assets [Member]
Derivative [Line Items]
Derivative Assets							0		$ 12
Derivative Liabilities							0		0
Accrued Liabilities [Member]
Derivative [Line Items]
Derivative Assets							0		0
Derivative Liabilities							$ 759		$ 616
Selling, General and Administrative Expenses [Member]
Derivative [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ (380)	$ (513)	$ (642)	$ (660)
Cost of Sales [Member]
Derivative [Line Items]
Gain (Loss) on Sale of Commodity Contracts	$ (159)	$ (100)	$ (491)	$ 214
212234 Copper Ore and Nickel Ore Mining [Member]
Derivative [Line Items]
Investment Contract Weight \| lb					181,200	181,200	181,200	181,200
Canada, Dollars
Derivative [Line Items]
Derivative Liability, Notional Amount \| CAD								CAD 9,000
Mexico, Pesos
Derivative [Line Items]
Derivative Liability, Notional Amount \| MXN					MXN 90,000
Canada, Dollars
Derivative [Line Items]
Derivative Liability, Notional Amount \| £						£ 4,500

Fair Value Measurements Level 4 (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities, Amortized Cost Basis

$ 6,675

$ 7,358

Business Combination, Contingent Consideration, Liability

7,579

8,332

4,557

2,500

Unrealized Gain on AFS Securities

904

974

Unrealized Loss on AFS Securities

^[1]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

^[2]

231,360

167,689

^[3]

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[3]

759

616

^[4]

7,579

8,332

^[4]

2,707

3,757

Business Combination, Contingent Consideration, Liability

^[5]

1,639,461

621,075

^[6]

4,557

2,500

Capital Additions [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

800

Business Combination, Consideration Transferred

1,561

Reductions and Payout [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

(122)

Foreign Currency Gain (Loss) [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

^[7]

(182)

Cost of Sales [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Gain (Loss) on Sale of Commodity Contracts

(159)

$ (100)

(491)

$ 214

Equity Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities, Amortized Cost Basis

^[8]

4,681

Unrealized Gain on AFS Securities

^[8]

4,933

4,681

^[8]

252

Unrealized Loss on AFS Securities

^[1],[8]

Mutual Funds [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities, Amortized Cost Basis

1,994

2,677

Unrealized Gain on AFS Securities

2,646

3,651

652

974

Unrealized Loss on AFS Securities

^[1]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

^[2]

207,525

148,944

^[3]

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[3]

^[4]

7,579

8,332

^[4]

2,707

3,757

Business Combination, Contingent Consideration, Liability

^[5]

^[6]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

^[2]

23,835

18,745

^[3]

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[3]

759

616

^[4]

^[4]

Business Combination, Contingent Consideration, Liability

^[5]

1,642,034

641,131

^[6]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

^[2]

^[3]

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[3]

^[4]

^[4]

Business Combination, Contingent Consideration, Liability

^[5]

^[6]

$ 4,557

$ 2,500

[1]	(2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.
[2]	Money market fund holdings are classified as level two as active market quoted prices are not available
[3]	The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[4]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment.
[5]	We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[6]	Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
[7]	Reported in other comprehensive income (loss).
[8]	(1) Our marketable equity securities have been in a unrealized loss position for less than 12 months

Subsequent Events Level 4 (Details) - Nov. 02, 2015	£ / shares	$ / shares
United States of America, Dollars
Subsequent Event [Line Items]
Value of transaction per Synergy Share \| $ / shares		$ 38.17
United Kingdom, Pounds
Subsequent Event [Line Items]
Value of transaction per Synergy Share \| £ / shares	£ 24.80

Restructuring (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Mar. 31, 2015

FY 2014 Restructuring Plan [Member]

Restructuring Charges

^[1]

$ (193)

$ (1,076)

$ (657)

$ (427)

Restructuring and Related Cost, Cost Incurred to Date

Restructuring Charges

(193)

$ (1,076)

(657)

$ (427)

18,815

Restructuring Reserve

1,085

$ 2,887

FY 2014 Restructuring Plan [Member] | Cost of Sales [Member]

Restructuring and Related Cost, Cost Incurred to Date

8,095

FY 2014 Restructuring Plan [Member] | Restructuring Charges [Member]

Restructuring and Related Cost, Cost Incurred to Date

$ 10,720

[1]	See Note 2 titled, "Restructuring" for more information related to restructuring

Business Acquisitions (Details)
$ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2015

USD ($)

Dec. 31, 2014

USD ($)

Dec. 31, 2015

USD ($)

Dec. 31, 2014

USD ($)

Mar. 31, 2015

USD ($)

Nov. 02, 2015

£ / shares

Nov. 02, 2015

USD ($)

$ / shares

Jun. 30, 2015

USD ($)

Business Acquisition, Pro Forma Revenue

^[1]

$ 681,254

$ 638,857

$ 1,928,779

$ 1,831,740

Business Acquisition, Pro Forma Income (Loss) from Continuing Operations before Changes in Accounting and Extraordinary Items, Net of Tax

^[1]

45,910

$ 39,406

118,388

$ 111,046

Synergy Combination Cash Consideration

$ 402,494

Synergy Combination Total Stock Consideration

1,887,479

FV of consideration available to vested Synergy share option holders

$ 3,626

STERIS plc total ordinary shares for consideration | shares

25,848,798

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

806,526

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

^[2]

2,302,355

STERIS Closing Stock Price at 10/10/2014 | $ / shares

$ 73.02

Business Combination, Contingent Consideration, Liability

4,557

$ 2,500

Other Acquisitions [Member]

Business Combination, Contingent Consideration, Liability

$ 1,760

Contingent liabilities Acquired Synergy Combination

7,082

Liability for Uncertain Tax Positions, Noncurrent

5,521

Business Combination, Acquisition Related Costs

$ 2,289,973

63,174

$ 2,293,599

Black Diamond [Member]

Business Combination, Contingent Consideration, Liability

800

Econopak [Member] [Member]

Business Combination, Acquisition Related Costs

2,379

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents

^[2]

53,057

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents

^[2]

103,052

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

^[2]

104,666

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

^[2]

30,074

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

^[2]

534,879

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other

^[2]

19,708

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

^[2]

806,526

Goodwill

^[2]

1,415,274

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

^[2]

2,964,184

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

^[2]

(110,727)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

^[2]

321,082

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

^[2]

(230,020)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

^[2]

(661,829)

Operating Profit (loss) From Synergy Included in Consolidated Totals

^[2]

(1,659)

Trade Names [Member]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

64,645

Econopak [Member] [Member]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents

^[2]

1,108

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

176,260

^[2]

4,161

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

^[2]

1,926

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

^[2]

946

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other

^[2]

1,621

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

^[2]

67,189

Business Acquisition, Goodwill, Expected Tax Deductible Amount

^[2]

100,782

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

^[2]

177,733

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

^[2]

(1,473)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

^[2]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

^[2]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

^[2]

(1,473)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

^[2]

176,260

Other Acquisitions [Member]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents

^[2]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

41,344

^[2]

3,859

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

^[2]

1,108

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

^[2]

1,979

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other

^[2]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

^[2]

13,631

Business Acquisition, Goodwill, Expected Tax Deductible Amount

^[2]

22,093

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

^[2]

42,670

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

^[2]

(1,277)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

^[2]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

^[2]

(49)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

^[2]

(1,326)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

^[2]

41,344

Black Diamond [Member]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents

^[2]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

46,766

^[2]

2,966

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

^[2]

3,309

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

^[2]

607

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other

^[2]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

^[2]

13,500

Business Acquisition, Goodwill, Expected Tax Deductible Amount

^[2]

36,654

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

^[2]

57,079

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

^[2]

(4,525)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

^[2]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

^[2]

(5,788)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

^[2]

(10,313)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

^[2]

46,766

Deferred Purchase Price of Acquired Entity

$ 5,870

Technology-Based Intangible Assets [Member]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

24,627

United Kingdom, Pounds

Value of transaction per Synergy Share | £ / shares

£ 24.80

United States of America, Dollars

Value of transaction per Synergy Share | $ / shares

$ 38.17

Capital Addition Purchase Commitments [Member]

Business Combination, Consideration Transferred

1,561

Property, Plant and Equipment, Estimated Useful Lives

17 years

Property, Plant and Equipment, Estimated Useful Lives

10 years

Customer Relationships [Member]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

$ 717,254

Trade Names [Member] | Synergy Health plc [Member]

Property, Plant and Equipment, Estimated Useful Lives

10 years

Technology-Based Intangible Assets [Member] | Synergy Health plc [Member]